An investigation on behalf of investors, who currently hold shares of Corium International, Inc. (NASDAQ: CORI), was announced concerning whether the takeover of Corium International, Inc. by Gurnet Point Capital is unfair to NASDAQ: CORI stockholders.

The investigation by a law firm concerns whether certain officers and directors of Corium International, Inc breached their fiduciary duties owed to NASDAQ: CORI investors in connection with the proposed acquisition.

Menlo Park, CA based Corium International, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of specialty pharmaceutical products in transdermal and transmucosal delivery systems.
On October 11, 2018, Corium International, Inc. (Nasdaq: CORI) announced that it has entered into a merger agreement under which Gurnet Point Capital (GPC), a private investment firm focused on the healthcare and life sciences sectors, will acquire Corium International, Inc. (NASDAQ: CORI).. Under the terms of the merger agreement, GPC will pay $12.50 per share in cash upon the closing.

However, given that at least one analyst has set the high target price for NASDAQ:CORI shares at $13.00 per share, the investigation concerns whether the offer is unfair to NASDAQ: CORI stockholders.

In addition, given that Coriums largest stockholder, Essex Woodlands, has already entered into a support agreement to tender its shares in this transaction, the investigation concerns whether the Corium International Board of Directors undertook an adequate sales process, adequately shopped the company before entering into the transaction, maximized shareholder value by negotiating the best price, and acted in the shareholders' best interests in connection with the proposed sale.